A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Clinical trial NCT03401112 · COMPLETED

Trial details

NCT number: NCT03401112
Sponsor: Cardurion Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Sickle Cell Disease

Start date: 2018-01-26
Primary completion: 2020-08-28
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.